Comment Takeaways (Score 1) 20
GLP-1 agonist didn't stop progression of AD in patients who were already on the disease course. I haven't read the protocol (if they enrolled in the EU it's out there somewhere), but I'd bet that the inclusion criteria included something about amyloid positivity, either in the blood, CSF, or from PET imaging.
What does that mean? It means that GLP-1 agonists may still prevent AD from being as likely to occur through indirect mechansims (i.e., obesity is tied to AD, less likelihood of developing AD if healthy weight), but probably can't slow it down once it's started, e.g., amyloid is laid out and tau is starting to pile up along that trailblaze from the amyloid.
Congrats, you've read an actual intelligent comment from someone with relevant knowledge and experience.